|
Index | - | P/E | - | EPS (ttm) | -1.44 | Insider Own | 52.96% | Shs Outstand | 9.14M | Perf Week | -44.18% |
Market Cap | 5.20M | Forward P/E | - | EPS next Y | -0.99 | Insider Trans | 0.00% | Shs Float | 3.21M | Perf Month | -53.33% |
Income | -9.30M | PEG | - | EPS next Q | -0.23 | Inst Own | 6.80% | Short Float | 10.01% | Perf Quarter | -89.81% |
Sales | - | P/S | - | EPS this Y | -100.90% | Inst Trans | -3.12% | Short Ratio | 0.09 | Perf Half Y | -88.14% |
Book/sh | 1.28 | P/B | 0.44 | EPS next Y | 16.10% | ROA | - | Target Price | 12.00 | Perf Year | -85.02% |
Cash/sh | 0.56 | P/C | 1.02 | EPS next 5Y | - | ROE | - | 52W Range | 0.49 - 10.36 | Perf YTD | -90.48% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -94.50% | Beta | - |
Dividend % | - | Quick Ratio | 2.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | 16.33% | ATR | 0.21 |
Employees | 3 | Current Ratio | 2.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 27.82 | Volatility | 27.24% 19.33% |
Optionable | No | Debt/Eq | 0.03 | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.04 | Prev Close | 0.57 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 3.70M | Price | 0.57 |
Recom | 2.00 | SMA20 | -52.64% | SMA50 | -75.70% | SMA200 | -88.62% | Volume | 29,748 | Change | 0.11% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite